CompletedPhase 1NCT00646230
N2004-03: Intravenous Fenretinide in Treating Young Patients With Recurrent or Resistant Neuroblastoma
Studying Neuroblastoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nant Operations Center
- Principal Investigator
- Barry J. Maurer, MD, PhD, M.D., Ph.DTexas Tech University Health Sciences Center
- Intervention
- fenretinide(drug)
- Enrollment
- 17 enrolled
- Eligibility
- 0-30 years · All sexes
- Timeline
- 2006 – 2012
Study locations (13)
- Childrens Hospital Los Angeles, Los Angeles, California, United States
- Lucile Packard Children's Hospital at Stanford University Medical Center, Palo Alto, California, United States
- UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
- AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus, Atlanta, Georgia, United States
- University of Chicago Comer Children's Hospital, Chicago, Illinois, United States
- Children's Hospital Boston, Boston, Massachusetts, United States
- C.S. Mott Children's Hospital at University of Michigan Medical Center, Ann Arbor, Michigan, United States
- Morgan Stanley Children's Hospital of New York-Presbyterian, New York, New York, United States
- Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
- Cook Children's Medical Center - Fort Worth, Fort Worth, Texas, United States
- Texas Children's Cancer Center and Hematology Service at Texas Children's Hospital, Houston, Texas, United States
- Children's Hospital and Regional Medical Center - Seattle, Seattle, Washington, United States
- Hospital for Sick Children, Toronto, Ontario, Canada
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00646230 on ClinicalTrials.govOther trials for Neuroblastoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2, PHASE3NCT07549321A Safety and Efficacy Study of hu14 in High-Risk Neuroblastoma PatientsRenaissance Pharma Ltd.
- RECRUITINGPHASE1, PHASE2NCT06625190Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid TumorsUniversity of Florida
- RECRUITINGPHASE1NCT07172958Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)Children's National Research Institute
- RECRUITINGPHASE2NCT07085338A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory NeuroblastomaSt. Jude Children's Research Hospital
- RECRUITINGPHASE1, PHASE2NCT07399821An Imaging Study of Anti-GD2-800CW in Patients With NeuroblastomaPrincess Maxima Center for Pediatric Oncology
- RECRUITINGPHASE1NCT06995872Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory NeuroblastomaNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT06814496Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsUniversity of Arizona
- RECRUITINGPHASE1NCT07087002GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young AdultsStanford University